Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Smętna Str. 12, 31-343, Kraków, Poland.
Psychopharmacology (Berl). 2020 Jan;237(1):231-248. doi: 10.1007/s00213-019-05362-5. Epub 2019 Oct 25.
Several findings indicate that early-life dysfunction of N-methyl-D-aspartate (NMDA) receptors might cause schizophrenia-like abnormalities in adulthood that might be induced by impairments in epigenetic regulation.
In the present study, we investigated whether postnatal blockade of NMDA receptors (within the first 3 weeks of life) by the competitive antagonist CGP 37849 (CGP) might affect some epigenetic markers in the adult medial prefrontal cortex (mPFC).
Histone H3 phosphorylation at serine 10 (H3S10ph), histone H3 acetylation at lysine 9 or 14 (H3K9ac or H3K14ac, respectively), or expression of histone deacetylase (HDAC) 2, HDAC5, myocyte enhancer factor (MEF) 2D and activity-regulated cytoskeleton-associated protein (Arc) were analysed. Moreover, we also evaluated whether the deacetylase inhibitor sodium butyrate (SB; 1.2 mg/kg, ip) could prevent behavioural and neurochemical changes in the mPFC induced by CGP during memory retrieval in the trace fear conditioning paradigm.
The results showed that CGP administration increased the number of H3S10ph nuclei but did not affect H3K9ac and H3K14ac or HDAC2 protein levels. However, CGP administration altered the HDAC5 mRNA and protein levels and increased the mRNA and protein levels of MEF2D. CGP also increased Arc mRNA, which was correlated with an increase in the amount of Arc DNA bound to MEF2D. SB given 2 h after training prevented impairment of the freezing response and disruption of epigenetic markers (H3S10ph, HDAC5, MEF2D) and Arc expression during memory retrieval induced by CGP administration.
The early-life blockade of NMDA receptors impairs some epigenetic regulatory processes in the mPFC that are involved in fear memory formation.
有几项研究结果表明,N-甲基-D-天冬氨酸(NMDA)受体在生命早期的功能障碍可能导致成年期出现类似精神分裂症的异常,而这种异常可能是由于表观遗传调控受损引起的。
在本研究中,我们研究了在生命的前 3 周内通过竞争性拮抗剂 CGP 37849(CGP)阻断 NMDA 受体是否会影响成年内侧前额叶皮层(mPFC)中的一些表观遗传标记物。
分析组蛋白 H3 在丝氨酸 10 处的磷酸化(H3S10ph)、组蛋白 H3 在赖氨酸 9 或 14 处的乙酰化(H3K9ac 或 H3K14ac,分别)、组蛋白去乙酰化酶(HDAC)2、HDAC5、肌细胞增强因子 2D(MEF2D)和活性调节细胞骨架相关蛋白(Arc)的表达。此外,我们还评估了去乙酰化酶抑制剂丁酸钠(SB;1.2mg/kg,ip)是否可以防止 CGP 在痕迹恐惧条件反射记忆检索期间对 mPFC 中的行为和神经化学变化的影响。
结果表明,CGP 给药增加了 H3S10ph 核的数量,但不影响 H3K9ac 和 H3K14ac 或 HDAC2 蛋白水平。然而,CGP 给药改变了 HDAC5 mRNA 和蛋白水平,并增加了 MEF2D 的 mRNA 和蛋白水平。CGP 还增加了 Arc mRNA 的水平,这与 MEF2D 结合的 Arc DNA 量的增加有关。训练后 2 小时给予 SB 可防止 CGP 给药引起的冻结反应受损以及表观遗传标记物(H3S10ph、HDAC5、MEF2D)和 Arc 表达的破坏,从而在记忆检索过程中发生。
生命早期 NMDA 受体的阻断会损害 mPFC 中一些参与恐惧记忆形成的表观遗传调控过程。